• TFBS Bioscience Partners with Medigen Vaccine Biologics to Support Process Development for a Second-Generation Multivalent Enterovirus Vaccine

  2026-08-24 TFBS Bioscience Partners with Medigen Vaccine Biologics to Support Process Development for a Second-Generation Multivalent Enterovirus Vaccine TFBS Bioscience, Inc. (TWSE: 6939; Headquarters: New Taipei City, Taiwan; “TFBS”) today announced a new phase of collaboration with Medigen Vaccine Biologics Corporation (TWSE: 6547; “MVC”). Under this collaboration, TFBS will provide contract development and manufacturing organization (CDMO) services for MVC’s second-generation multivalent enterovirus vaccine. Learn more

• TFBS Bioscience and Adara Bio Collaborate to Accelerate Development of AAV-based Gene Therapy

  2026-07-17 TFBS Bioscience and Adara Bio Collaborate to Accelerate Development of AAV-based Gene Therapy TFBS Bioscience, Inc. (Headquarters: New Taipei City, Taiwan; hereinafter “TFBS”), a leading viral vector CDMO and CRO service provider in Taiwan, and Adara Bio Pty Ltd (hereinafter “Adara Bio”), an Australian-based company, announce a collaboration agreement for adeno-associated virus (AAV) vector manufacturing at BIO Asia 2026 in Taipei. Under the partnership, Adara Bio, a biotechnology company focused on the development of next generation RNA medicines for inherited retinal diseases (IRDs), will leverage TFBS's expertise in contract development and manufacturing organisation (CDMO) services to support its preclinical and future clinical programs. Learn more

• TFBS Bioscience and QIMR Berghofer Sign MOU to Advance Global CGT Collaboration in Cell and Gene Therapy

  2026-05-28 TFBS Bioscience and QIMR Berghofer Sign MOU to Advance Global CGT Collaboration in Cell and Gene Therapy TFBS Bioscience, Inc. (Headquarters: New Taipei City, Taiwan; hereinafter “TFBS”) and QIMR Berghofer Medical Research Institute (Headquarters: Herston, Queensland, Australia; hereinafter “QIMR Berghofer”) jointly announced the signing of a Memorandum of Understanding (MOU) on April 29, 2026, establishing a strategic partnership in the field of cell and gene therapy (CGT). The collaboration aims to combine the expertise and resources of both organizations to advance the development of innovative therapies and expand international market opportunities. Learn more

• TFBS Bioscience and Tottori University Hold Signing Ceremony for Manufacturing Partnership to Commercialize a Next-Generation Cancer Therapeutic Vaccinia Virus

  2025-12-26 TFBS Bioscience and Tottori University Hold Signing Ceremony for Manufacturing Partnership to Commercialize a Next-Generation Cancer Therapeutic Vaccinia Virus TFBS Bioscience, Inc. (Headquarters: New Taipei City, Taiwan; hereinafter “TFBS”) and Tottori University (Headquarters: Tottori City, Tottori Prefecture; hereinafter “Tottori University”) are pleased to announce that they have entered into a manufacturing services agreement for the future development, commercialization, and practical application of FUVAC121, a next-generation vaccinia virus for cancer therapy developed by Professor Takafumi Nakamura and colleagues at the Faculty of Medicine, Tottori University (hereinafter, the “Partnership”). The signing ceremony was held on December 22, 2025, at the Tottori Campus of Tottori University. Learn more

• TFBS Bioscience and Tottori University Announce Business Alliance for Manufacturing of Next-Generation Oncolytic Virus for Cancer Treatment

  2025-12-08 TFBS Bioscience and Tottori University Announce Business Alliance for Manufacturing of Next-Generation Oncolytic Virus for Cancer Treatment TFBS Bioscience, Inc. (Headquarters: New Taipei City, Taiwan, hereinafter "TFBS") and the National University Tottori University (Headquarters: Tottori City, Tottori Prefecture, Japan, hereinafter "Tottori University") have entered into a business alliance (hereinafter, "the Alliance") regarding the manufacturing of the next-generation vaccinia virus, FUVAC121, developed by Professor Takafumi Nakamura and his team at the Faculty of Medicine, Tottori University. The Alliance aims to advance the future development, commercialization, and practical application of FUVAC121. Learn more